Oral Featured Posters最新文献

OP022/#597 Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: a propensity-score matching analysis 优化晚期上皮性卵巢癌新辅助化疗周期数:倾向评分匹配分析

Oral Featured Posters Pub Date : 2021-11-01 DOI: 10.1136/ijgc-2021-igcs.39

A. Rosati, C. Marchetti, F. De Felice, S. Boccia, L. Vertechy, M. Pavone, E. Palluzzi, G. Scambia, A. Fagotti

{"title":"OP022/#597 Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: a propensity-score matching analysis","authors":"A. Rosati, C. Marchetti, F. De Felice, S. Boccia, L. Vertechy, M. Pavone, E. Palluzzi, G. Scambia, A. Fagotti","doi":"10.1136/ijgc-2021-igcs.39","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.39","url":null,"abstract":"Objectives To identify gene expression profiles and interacting pathways in BRCA1- and BRCA2- associated high grade serous ovarian cancer (HGSOC) as compared to one another and to BRCA wild type, homologous recombination proficient (HRP) tumors. Methods of total samples, and HRP were analyzed. Gene was collected from Tempus and were to identify differ-entially expressed genes (DEG) with p-value and fold change of Meta and pathway analyses were performed among BRCA1, BRCA2 and HRP groups using Venn diagram and Advaita Bio ’ s iPathwayGuide. BRCA mutated and wild type (wt) ID8 mouse cell lines were used for protein expression and seahorse assay for metabolism analysis. Results From 18,284 genes with measured expression, 843 (4.6%) DEG were found between BRCA2 vs BRCA1, 748 (4.1%) between BRCA2 vs HRP and 1,858 (10.2%) between BRCA1 and HRP. On meta-analysis of the three comparisons, pathway analysis revealed significant involvement of Wnt signaling pathway and oxidative phosphorylation unique to BRCA2 group compared to fibroblast growth factor signaling PI3K-Akt signaling for BRCA1. Western blot analysis con-firmed higher expression of oxidative phosphorylation com-plex proteins in BRCA1/BRCA2 mutated lines and differential expression of b catenin between BRCA mutated versus wt cell lines. Seahorse assay showed higher oxidative consumption rate in BRCA mutated versus wt cells. Conclusions Our study identified differential pathway regula-tion for BRCA2 versus BRCA1 associated HGSOC, suggesting each should be considered a separate phenotype with unique opportunities for targeted therapy.","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73102437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

OP008/#194 P53ABN molecular subtype encompasses a morphologically diverse subset of endometrial cancers and identifies therapeutic opportunities to improve outcomes OP008/#194 P53ABN分子亚型涵盖了子宫内膜癌的形态多样化亚群，并确定了改善预后的治疗机会

Oral Featured Posters Pub Date : 2021-11-01 DOI: 10.1136/ijgc-2021-igcs.25

A. Jamieson, E. Thompson, J. Huvila, S. Leung, A. Lum, L. Helpman, S. Salvador, J. Irving, K. Grondin, A. Lytwyn, C. Parra-Herran, S. Offman, M. Kinloch, M. Plante, D. Vicus, A. Talhouk, S. Scott, D. Huntsman, C. Gilks, J. Mcalpine

引用次数: 0

OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer mirvetuximab soravtansine (MIRV)和rucaparib治疗复发性子宫内膜癌、卵巢癌、输卵管癌或原发性腹膜癌的I期研究

Oral Featured Posters Pub Date : 2021-11-01 DOI: 10.1136/ijgc-2021-igcs.24

F. Backes, J. Fowler, L. Copeland, L. Wei, D. O’Malley, D. Cohn, C. Cosgrove, J. Hays, K. Bixel

引用次数: 0

OP024/#182 Findings and outcomes in a post-vaccination cohort of young women under 25 years attending a tertiary colposcopy service 接种疫苗后参加第三次阴道镜检查的25岁以下年轻女性队列的发现和结果

Oral Featured Posters Pub Date : 2021-11-01 DOI: 10.1136/ijgc-2021-igcs.41

C. Yim, Y. Jayasinghe, D. Wrede, J. Tan

{"title":"OP024/#182 Findings and outcomes in a post-vaccination cohort of young women under 25 years attending a tertiary colposcopy service","authors":"C. Yim, Y. Jayasinghe, D. Wrede, J. Tan","doi":"10.1136/ijgc-2021-igcs.41","DOIUrl":"https://doi.org/10.1136/ijgc-2021-igcs.41","url":null,"abstract":"comes in high grade ovarian cancer (HGOC) stratified by homologous recombination deficiency (HRD) status undergoing frontline and/or maintenance therapy. Methods We performed a retrospective analysis of HGOC from April 2013 to June 2019. Clinical outcomes were analyzed by (1) germline BRCA+ (2) germline BRCA and somatic BRCA/HRD+, or (3) BRCA-/HRD-. Progression free (PFS) and overall survival (OS) were estimated using KaplanMeier methods and modeled via Cox proportional hazards regression. Results 187 patients met inclusion criteria. 106 patients had germline BRCA mutation, 26 somatic BRCA/HRD+, and 55 BRCA/HRD-. Multivariate analysis for PFS revealed that age (HR 1.02, 95% CI 1.00–1.04), p=0.01), stage (HR 5.7, 95% CI 1.39–23.4, p=0.02), R0 resection at TRS (HR 0.41, 95% CI 0.21–0.83, p=0.01), and BRCA/HRDstatus (HR 1.63, 95% CI 1.07–2.48, p=0.02) were significant factors impacting PFS. Multivariate analysis for OS revealed age (HR 1.07, 95% CI 1.03–1.10, p<0.001) and R0 resection at TRS (HR 0.19, 95% CI 0.08–0.44, p<0.001) were significant factors impacting OS. 17 of 187 patients received PARPi maintenance therapy. All harbored a germline or somatic mutation in BRCA1/ BRCA2 (14) or had tumors characterized by HRD (3). Multivariate analysis for PFS revealed that PARPi maintenance therapy (HR 0.14 95% CI 0.04–0.57), p=0.006) was a significant factor impacting PFS. Conclusions Germline BRCA-mutant, somatic BRCA/HRD+ HGOC was associated with improved PFS and OS regardless of primary TRS or NACT. BRCA-/HRDwas a negative prognostic factor for survival in HGOC. PARPi maintenance therapy was associated with improved PFS in Germline BRCAmutant, somatic BRCA/HRD+ HGOC","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86931050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

OP006/#489 Survival impact of ontogenetic surgery for newly diagnosed cervical cancer 新诊断宫颈癌的个体发生手术对生存率的影响

Oral Featured Posters Pub Date : 2021-11-01 DOI: 10.1136/ijgc-2021-igcs.23

U. Kim, D. Kim, S. Park, M. Lee, H. Chung, J. Kim, N. Park, Y. Song, H.S. Kim

引用次数: 0

OP002/#213 Is cervical excision before radical hysterectomy associated with better oncologic outcomes for patients with early stage cervical carcinoma ? 根治性子宫切除术前宫颈切除与早期宫颈癌患者更好的肿瘤预后相关吗?

Oral Featured Posters Pub Date : 2021-11-01 DOI: 10.1136/ijgc-2021-igcs.19

D. Nasioudis, E. Ko, A. Haggerty, L. Cory, R. Giuntoli Ii, S. Kim, N. Latif

引用次数: 0

OP025/#128 Comprehensive perioperative care program to improve same-day discharge after minimally invasive gynecologic oncology surgery OP025/#128综合围手术期护理方案，改善微创妇科肿瘤手术后当日出院

Oral Featured Posters Pub Date : 2021-11-01 DOI: 10.1136/ijgc-2021-igcs.42

Rs Kim, S. Laframboise, G. Nelson, S. McCluskey, L. Avery, N. Kujbid, A. Zia, M. Bernardini, S. Ferguson, T. May, L. Hogen, P. Cybulska, G. Bouchard-Fortier

引用次数: 0

OP015/#492 Further stratification of no specific molecular profile (NSMP/P53WT) endometrial carcinomas to refine prognosis and identify therapeutic opportunities 无特异性分子谱(NSMP/P53WT)子宫内膜癌的进一步分层以改善预后并确定治疗机会

Oral Featured Posters Pub Date : 2021-11-01 DOI: 10.1136/ijgc-2021-igcs.32

E. Thompson, J. Huvila, D. Chiu, S. Leung, A. Lum, A. Jamieson, M. Köbel, M. Plante, S. Scott, S. Salvador, D. Vicus, L. Helpman, M. Kinloch, K. Grondin, J. Irving, A. Talhouk, D. Huntsman, S. Kommoss, C. Gilks, J. Mcalpine

引用次数: 2

OP027/#469 Electronic patient-reported outcome (EPRO) measures in gynecologic oncology: initial experience after workflow implementation 电子患者报告结果(EPRO)措施在妇科肿瘤学:工作流程实施后的初步经验

Oral Featured Posters Pub Date : 2021-11-01 DOI: 10.1136/ijgc-2021-igcs.44

J. Noh, C. Choi, T. Kim, J.-W. Lee, Y. Lee

引用次数: 0

OP021/#475 Separating the BRCA1 and BRCA2 phenotype, a pathway analysis 分离BRCA1和BRCA2表型，途径分析

Oral Featured Posters Pub Date : 2021-11-01 DOI: 10.1136/ijgc-2021-igcs.38

L. Rubinsak, S. Kim, H. Jang, G. Mor, S. Galoforo, H. Ramos, R. Rattan, A. Alvero, R. Gogoi

引用次数: 0